Business Context and Reporting Period
This Form 8-K is a current report filed by DFB Healthcare Acquisitions Corp. (DFB) on October 15, 2019. The filing details amendments to the proposed business combination between DFB and AdaptHealth Holdings LLC (Adapt). The transaction aims to make Adapt a partially owned subsidiary of DFB. DFB is an emerging growth company listed on The Nasdaq Stock Market LLC.
Key Financial Metrics and Transaction Terms
This filing does not contain historical financial statements, revenue, profit, or cash flow data for DFB or Adapt. The financial details provided relate to the structure of the proposed transaction and private investment:
- PIPE Investment: Deerfield Private Design Fund IV, L.P. and RAB Ventures (DFB) LLC agreed to purchase between 5,000,000 and 12,500,000 shares of DFB common stock at $10.00 per share.
- Investment Triggers: The number of shares purchased depends on DFB's "Available Cash" immediately prior to closing:
- If Available Cash is $75 million or less: 12,500,000 shares.
- If Available Cash is between $75 million and $100 million: 10,000,000 to 12,500,000 shares (at Deerfield's discretion).
- If Available Cash is between $100 million and $200 million: 10,000,000 shares.
- If Available Cash exceeds $200 million: Shares calculated to reach a total of $300 million (minus Available Cash), divided by $10, with a minimum of 5,000,000 shares.
- Lock-Up Periods: 9 months for the first 7,500,000 PIPE shares purchased by Deerfield; 3 months for any excess shares.
- Sponsor Assignment: The Sponsor will transfer between 2,437,500 and 2,500,000 shares and between 1,690,000 and 1,733,333 warrants to Adapt or its designees for no consideration, contingent on the final PIPE share count.
Material Changes Versus Prior Period
The filing describes amendments to the original Merger Agreement dated July 8, 2019. Key changes include:
- Removal of Cash Condition: The minimum cash closing condition previously required in the Agreement has been removed.
- New Regulatory Condition: A new condition was added requiring the absence of any investigation, review, or action concerning a material violation of healthcare law against Adapt by certain regulatory authorities since the date of the Amendment.
- Indemnification: Added a provision obligating the A Blocker Seller to indemnify DFB against liabilities of the A Blocker, including tax liabilities, arising prior to Closing.
- Corporate Documents: Amended and restated the forms of the certificate of incorporation and the tax receivables agreement to be adopted at Closing.
Guidance, Outlook, Risks, and Contingencies
Outlook and Status: The transaction is subject to stockholder approval and regulatory conditions. DFB has filed a preliminary proxy statement and three amendments thereto. The definitive proxy statement will be mailed to stockholders for a special meeting.
Risks and Contingencies:
- Regulatory Investigations: The new closing condition specifically addresses the risk of healthcare law investigations against Adapt.
- Transaction Failure: Risks include failure to obtain regulatory approvals, delays, or failure to secure stockholder approval from DFB or Adapt.
- Redemptions: The amount of redemption requests by DFB stockholders could impact the transaction economics.
- Forward-Looking Statements: Management disclaims any obligation to update forward-looking statements regarding projections, market opportunity, or the closing of the transaction.
Important Facts for Investor Verification
- Verify the status of any regulatory investigations into AdaptHealth regarding healthcare law violations, as this is now a specific closing condition.
- Confirm the final "Available Cash" amount at closing to determine the exact number of PIPE shares to be issued and the resulting dilution.
- Review the definitive proxy statement for detailed risk factors and the specific terms of the tax receivables agreement.
- Monitor the redemption rate of DFB stockholders, which will affect the cash available for the transaction and the final capital structure.
- Check for updates on the approval status of the transaction by DFB and Adapt stockholders.